At a glance
ClinicalIndex Comparison RecordN/ACompleted· 406 enrolled
Drug / intervention
diffusion-weighted magnetic resonance imagingprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)
American College of Radiology Imaging Network·interventional·Posted Mar 27, 2012·Updated Apr 15, 2024
In Brief
A clinical study evaluating diffusion-weighted magnetic resonance imaging for Breast Cancer. Completed, enrolled 406 participants across 7 sites.
Detailed Summary
RATIONALE: Imaging procedures, such as diffusion-weighted magnetic resonance imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), may help in evaluating how well patients with breast cancer respond to treatment. PURPOSE: This research trial studies DWI and DCE-MRI in assessing treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartAug 2012
Primary CompletionJul 2018
Study CompletionJan 2020
TodayJul 2026
First PostedMar 27, 2012
Enrollment StartAug 27, 2012
Primary CompletionJul 19, 2018
Study CompletionJan 14, 2020
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 14.3 years ago
Interventions
diffusion-weighted magnetic resonance imagingprocedure
diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation